Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALLR
ALLR logo

ALLR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Allarity Therapeutics Inc (ALLR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.200
1 Day change
-8.40%
52 Week Range
2.350
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ALLR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows no strong proprietary buy signal, no recent news catalyst, neutral insider and hedge fund activity, and weak technical momentum. Given the lack of clear upside confirmation and the investor's long-term profile, the better call is to hold off rather than buy today.

Technical Analysis

The technical picture is mixed to weak. MACD histogram is negative at -0.0134, though it is contracting, which suggests downside momentum is easing but not yet reversed. RSI_6 at 40.768 is neutral-to-soft, showing no strong bullish momentum. Moving averages are converging, which often signals indecision rather than a confirmed uptrend. Price at 1.34 is slightly above the previous close of 1.31, but still below the pivot at 1.359, with nearby resistance at 1.46 and 1.522. Support sits at 1.257 and 1.195. Overall, the trend is not strong enough to justify an immediate buy.

Positive Catalysts

  • There are no recent news catalysts, no significant hedge fund accumulation, no insider buying trend, and no positive proprietary trading signal. The only mild positive is that MACD downside pressure is contracting, which could eventually support stabilization.

Neutral/Negative Catalysts

  • No news in the recent week, no recent congress trading data, neutral hedge fund activity, neutral insider activity, no AI Stock Picker signal, and no SwingMax signal. The stock trend model also suggests limited near-term upside with a projected -3.92% move over the next month. The latest financial snapshot was unavailable, so there is no supportive earnings-based catalyst to offset the weak setup.

Financial Performance

Financial performance data was not available because the latest quarterly snapshot returned an error. Since no quarter or growth figures were provided, there is no evidence here of accelerating revenue, earnings, or margin improvement to support a long-term buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. Based on the available information, Wall Street sentiment cannot be confirmed as bullish. With no positive rating momentum, no target raises, and no supporting catalysts, the analyst picture appears neutral at best.

Wall Street analysts forecast ALLR stock price to rise
1 Analyst Rating
Wall Street analysts forecast ALLR stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.310
sliders
Low
9.5
Averages
9.5
High
9.5
Current: 1.310
sliders
Low
9.5
Averages
9.5
High
9.5
Ascendiant
NULL -> Buy
initiated
$9
AI Analysis
2025-07-28
Reason
Ascendiant
Price Target
$9
AI Analysis
2025-07-28
initiated
NULL -> Buy
Reason
Ascendiant initiated coverage of Allarity with a Buy rating and $9 price target. The firm sees large market opportunities for the company's DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.

People Also Watch